Who is sponsoring NCT01515826?

NCT01515826 is sponsored by Alcon Research.

What drugs are being tested in NCT01515826?

Interventions: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel), Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution).

What is the status of NCT01515826?

NCT01515826 is currently WITHDRAWN.

Last reviewed 2014-03-24 · How we verify

Evaluation of the Safety and Efficacy of VIGADEXA Ophthalmic Gel Compared to VIGADEXA Ophthalmic Solution in Preventing Inflammation and Infection Following Cataract Surgery

NCT01515826 Phase 3 WITHDRAWN

The purpose of this study is to compare VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.075%) ophthalmic gel to VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.1%) ophthalmic solution in the prevention of postoperative inflammation and infection.

Details

Lead sponsor	Alcon Research
Phase	Phase 3
Status	WITHDRAWN
Start date	2014-03
Completion	2014-10

Conditions

Cataracts

Interventions

Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)
Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)

Primary outcomes

Percentage of patients with a score of 0 (<5 cells) for cells in the anterior chamber — Day 15 post-operative
As assessed by the investigator during slit-lamp examination.
Percentage of patients with no clinically evidenced bacterial infection — Day 15 post-operative
As assessed by the investigator during slit-lamp examination.